Lupin secures 180-day exclusivity for generic Lotemax SM gel in the U.S., set to launch from India's Pithampur facility.

• Product treats post-op eye inflammation and pain, with $29M annual U.S. sales in May 2025.
• Lupin, a global pharma leader, distributes in 100+ markets, offering branded, generic, and biotech products.
• Manufactured at Pithampur, India, the gel is a corticosteroid with complex formulation expertise.